|Bid||2.4200 x 3100|
|Ask||2.4500 x 1300|
|Day's Range||2.4200 - 2.5000|
|52 Week Range||2.2800 - 5.3900|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 08, 2021 - Nov. 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to...
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036NEWTON, Mass. and GENEVA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 17/196,416 for certain cl